Using insights into Pim1 structure to design new anticancer drugs

Current Pharmaceutical Design

Volumn 16, Issue 35, 2010, Pages 3964-3978

  Schenone, Silvia ^a   Tintori, Cristina ^b   Botta, Maurizio ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

Author keywords

Cancer; Inhibitors; Pim1; Serine threonine kinase; Structure based drug design; X ray

Indexed keywords

ANTINEOPLASTIC AGENT; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 6; INTERLEUKIN 7; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; PROTEIN BAD; PROTEIN P53; STAT PROTEIN; TRANSCRIPTION FACTOR RUNX3;

AMINO TERMINAL SEQUENCE; CELL CYCLE PROGRESSION; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; DOWN REGULATION; LARGE CELL LYMPHOMA; MURINE LEUKEMIA VIRUS; NONHUMAN; ONCOGENE C MYC; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; X RAY;

ANTINEOPLASTIC AGENTS; DRUG DESIGN; HUMANS; PROTO-ONCOGENE PROTEINS C-PIM-1;

EID: 79551625129     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210794454996     Document Type: Review

References (99)

1. Cuypers HT, Selten G, Quint W, et al. Murine leukemia virusinduced T-cell lymphomagenesis: integration of proviruses in a distinct chromosomal region. Cell 1984; 37: 141-50.
2. van der Lugt NM, Domen J, Verhoeven E, et al. Proviral tagging in E mu-myc transgenic mice lacking the Pim-1 proto-oncogene leads to compensatory activation of Pim-2. EMBO J 1995; 14: 2536-44.
3. Popivanova BK, Li YY, Zheng H, et al. Proto-oncogene, Pim-3 with serine/threonine kinase activity, is aberrantly expressed in human colon cancer cells and can prevent Bad-mediated apoptosis. Cancer Sci 2007; 98: 321-8.
4. Saris CJ, Domen J, Berns A. The pim-1 oncogene encodes two related protein-serine/threonine kinases by alternative initiation at AUG and CUG. EMBO J 1991; 10: 655-64
5. Xie Y, Xu K, Dai B, et al. The 44 kDa Pim-1 kinase directly interacts with tyrosine kinase Etk/BMX and protects human prostate cancer cells from apoptosis induced by chemotherapeutic drugs. Oncogene 2006; 25: 70-8.
6. Amson R, Sigaux F, Przedborski S, Flandrin G, Givol D, Telerman A. The human protooncogene product p33pim is expressed during fetal hematopoiesis and in diverse leukemias. Proc Natl Acad Sci USA 1989; 86: 8857-61.
7. Eichmann A, Yuan L, Bréant C, Alitalo K, Koskinen PJ. Developmental expression of pim kinases suggests functions also outside of the hematopoietic system. Oncogene 2000; 19: 1215-24.
8. Morwick T. Pim kinase inhibitors: a survey of the patent literature. Expert Opin Ther Patents 2010; 20: 193-212.
9. Wang Z, Bhattacharya N, Weaver M, et al. Pim-1: a serine/ threonine kinase with a role in cell survival, proliferation, differentiation and tumorigenesis. J Vet Sci 2001; 2: 167-79.
10. Peltola KJ, Paukku K, Aho TL, Ruuska M, Silvennoinen O, Koskinen PJ. Pim-1 kinase inhibits STAT5-dependent transcription via its interactions with SOCS1 and SOCS3. Blood 2004; 103: 3744-50.
11. Laird PW, van der Lugt NM, Clarke A, et al. In vivo analysis of Pim-1 deficiency. Nucleic Acids Res 1993; 21: 4750-5.
12. van der Lugt NM, Domen J, Verhoeven E, et al. Proviral tagging in E mu-myc transgenic mice lacking the Pim-1 proto-oncogene leads to compensatory activation of Pim-2. EMBO J 1995; 14: 2536-44.
13. Mikkers H, Nawijn M, Allen J, et al. Mice deficient for all PIM kinases display reduced body size and impaired responses to hematopoietic growth factors. Mol Cell Biol 2004; 24: 6104-15.
14. Bachmann M, Möröy T. The serine/threonine kinase Pim-1. Int J Biochem Cell Biol 2005; 37: 726-30.
15. Lilly M, Kraft A. Enforced expression of the Mr 33,000 Pim-1 kinase enhances factor-independent survival and inhibits apoptosis in murine myeloid cells. Cancer Res 1997; 57: 5348-55.
16. Bachmann M, Hennemann H, Xing PX, Hoffmann I, Möröy T. The oncogenic serine/threonine kinase Pim-1 phosphorylates and inhibits the activity of Cdc25C-associated kinase 1 (C-TAK1): a novel role for Pim-1 at the G2/M cell cycle checkpoint. J Biol Chem 2004; 279: 48319-28.
17. Bachmann M, Kosan C, Xing PX, Montenarh M, Hoffmann I, Möröy T. The oncogenic serine/threonine kinase Pim-1 directly phosphorylates and activates the G2/M specific phosphatase Cdc25C. Int J Biochem Cell Biol 2006; 38: 430-43.
18. Wang Z, Bhattacharya N, Mixter PF, Wei W, Sedivy J, Magnuson NS. Phosphorylation of the cell cycle inhibitor p21Cip1/WAF1 by Pim-1 kinase. Biochim Biophys Acta 2002; 1593: 45-55.
19. Zhang Y, Wang Z, Magnuson NS Pim-1 kinase-dependent phosphorylation of p21Cip1/WAF1 regulates its stability and cellular localization in H1299 cells. Mol Cancer Res 2007; 5: 909-22.
20. Morishita D, Katayama R, Sekimizu K, Tsuruo T, Fujita N. Pim kinases promote cell cycle progression by phosphorylating and down-regulating p27Kip1 at the transcriptional and posttranscriptional levels. Cancer Res 2008; 68: 5076-85.
21. Wood NT, Meek DW, Mackintosh C. 14-3-3 Binding to Pimphosphorylated Ser166 and Ser186 of human Mdm2--Potential interplay with the PKB/Akt pathway and p14(ARF). FEBS Lett 2009; 583: 615-20.
22. Wang Z, Bhattacharya N, Meyer MK, et al. Pim-1 negatively regulates the activity of PTP-U2S phosphatase and influences terminal differentiation and apoptosis of monoblastoid leukemia cells. Arch Biochem Biophys 2001; 390: 9-18.
23. Hu XF, Li J, Vandervalk S, Wang Z, Magnuson NS, Xing PX. PIM-1-specific mAb suppresses human and mouse tumor growth by decreasing PIM-1 levels, reducing Akt phosphorylation, and activating apoptosis. J Clin Invest 2009; 119: 362-75.
24. Aho TL, Sandholm J, Peltola KJ, Mankonen HP, Lilly M, Koskinen PJ. Pim-1 kinase promotes inactivation of the pro-apoptotic Bad protein by phosphorylating it on the Ser112 gatekeeper site. FEBS Lett 2004; 571: 43-9.
25. Macdonald A, Campbell DG, Toth R, McLauchlan H, Hastie CJ, Arthur JS. Pim kinases phosphorylate multiple sites on Bad and promote 14-3-3 binding and dissociation from Bcl-XL. BMC Cell Biol 2006; 7: 1.
26. Andina N, Didichenko S, Schmidt-Mende J, Dahinden CA, Simon HU. Proviral integration site for Moloney murine leukemia virus 1, but not phosphatidylinositol-3 kinase, is essential in the antiapoptotic signaling cascade initiated by IL-5 in eosinophils. J Allergy Clin Immunol 2009; 123: 603-11.
27. Didichenko SA, Spiegl N, Brunner T, Dahinden CA. IL-3 induces a Pim1-dependent antiapoptotic pathway in primary human basophils Blood 2008; 112: 3949-58.
28. Zhang F, Beharry ZM, Harris TE, et al. PIM1 protein kinase regulates PRAS40 phosphorylation and mTOR activity in FDCP1 cells. Cancer Biol Ther 2009; 8: 846-53.
29. Domen J, van der Lugt NM, Laird PW, Saris CJ, Berns A. Analysis of Pim-1 function in mutant mice. Leukemia 1993; 7 Suppl 2: S108-12.
30. Baxter EW, Blyth K, Donehower LA, Cameron ER, Onions DE, Neil JC Moloney murine leukemia virus-induced lymphomas in p53-deficient mice: overlapping pathways in tumor development? Virology 1996; 70: 2095-100.
31. Shirogane T, Fukada T, Muller JM, Shima DT, Hibi M, Hirano T. Synergistic roles for Pim-1 and c-Myc in STAT3-mediated cell cycle progression and antiapoptosis. Immunity 1999; 11: 709-19.
32. Zhang Y, Wang Z, Li X, Magnuson NS. Pim kinase-dependent inhibition of c-Myc degradation. Oncogene 2008; 27: 4809-19.
33. Zippo A, De Robertis A, Serafini R, Oliviero S. PIM1-dependent phosphorylation of histone H3 at serine 10 is required for MYCdependent transcriptional activation and oncogenic transformation. Nat Cell Biol 2007; 9: 932-44.
34. Zörnig M, Schmidt T, Karsunky H, Grzeschiczek A, Möröy T. Zinc finger protein GFI-1 cooperates with myc and pim-1 in T-cell lymphomagenesis by reducing the requirements for IL-2. Oncogene 1996; 12: 1789-801.
35. Kim HR, Oh BC, Choi JK, Bae SC. Pim-1 kinase phosphorylates and stabilizes RUNX3 and alters its subcellular localization. J Cell Biochem 2008; 105: 1048-58.
36. Zippo A, De Robertis A, Bardelli M, Galvagni F, Oliviero S. Identification of Flk-1 target genes in vasculogenesis: Pim-1 is required for endothelial and mural cell differentiation in vitro. Blood 2004; 103: 4536-44.
37. Brault L, Gasser C, Bracher F, Huber K, Knapp S, Schwaller J. PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers. Hematologica 2010; 95: 1004-1015.
38. Shah N, Pang B, Yeoh KG, et al. Potential roles for the PIM1 kinase in human cancer - a molecular and therapeutic appraisal. Eur J Cancer 2008; 44: 2144-51
39. Chen CN, Lin JJ, Chen JJ, et al. Gene expression profile predicts patient survival of gastric cancer after surgical resection. J Clin Oncol 2005; 23: 7286-95.
40. Le QT, Denko NC, Giaccia AJ. Hypoxic gene expression and metastasis. Cancer Metastasis Rev 2004; 23: 293-310.
41. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503-11.
42. Akasaka H, Akasaka T, Kurata M, et al. Molecular anatomy of BCL6 translocations revealed by long-distance polymerase chain reaction-based assays. Cancer Res 2000; 60: 2335-41.
43. Pasqualucci L, Neumeister P, Goossens T, et al. Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature 2001; 412: 341-6.
44. Kumar A, Mandiyan V, Suzuki Y, et al. Crystal structures of protooncogene kinase Pim1: a target of aberrant somatic hypermutations in diffuse large cell lymphoma. J Mol Biol 2005; 348: 183-93.
45. Gaidano G, Pasqualucci L, Capello D, et al. Aberrant somatic hypermutation in multiple subtypes of AIDS-associated non- Hodgkin lymphoma. Blood 2003; 102: 1833-41.
46. Libra M, Capello D, Gloghini A, et al. Analysis of aberrant somatic hypermutation (SHM) in non-Hodgkin's lymphomas of patients with chronic HCV infection. J Pathol 2005; 206: 87-91.
47. Montesinos-Rongen M, Van Roost D, Schaller C, Wiestler OD, Deckert M. Primary diffuse large B-cell lymphomas of the central nervous system are targeted by aberrant somatic hypermutation. Blood 2004; 103: 1869-75.
48. Deutsch AJ, Aigelsreiter A, Staber PB, et al. MALT lymphoma and extranodal diffuse large B-cell lymphoma are targeted by aberrant somatic hypermutation. Blood 2007; 109: 3500-4.
49. Deutsch AJ, Frühwirth M, Aigelsreiter A, Cerroni L, Neumeister P. Primary cutaneous marginal zone B-cell lymphomas are targeted by aberrant somatic hypermutation. J Invest Dermatol 2009; 129: 476-9.
50. Ionov Y, Le X, Tunquist BJ, et al. Pim-1 protein kinase is nuclear in Burkitt's lymphoma: nuclear localization is necessary for its biologic effects. Anticancer Res 2003; 23: 167-78.
51. Hsi ED, Jung SH, Lai R, et al. Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study. Leuk Lymphoma 2008; 49: 2081-90.
52. Dreyfus F, Sola B, Fichelson S, et al. Rearrangements of the Pim-1, c-myc, and p53 genes in Friend helper virus-induced mouse erythroleukemias. Leukemia 1990; 4: 590-4.
53. Amson R, Sigaux F, Przedborski S, Flandrin G, Givol D, Telerman A. The human protooncogene product p33pim is expressed during fetal hematopoiesis and in diverse leukemias. Proc Natl Acad Sci USA 1989; 86: 8857-61.
54. Nosaka T, Kitamura T. Pim-1 expression is sufficient to induce cytokine independence in murine hematopoietic cells, but is dispensable for BCR-ABL-mediated transformation. Exp Hematol 2002; 30: 697-702.
55. Nieborowska-Skorska M, Hoser G, Kossev P, Wasik MA, Skorski T. Complementary functions of the antiapoptotic protein A1 and serine/threonine kinase pim-1 in the BCR/ABL-mediated leukemogenesis. Blood 2002; 99: 4531-9.
56. Håkansson P, Segal D, Lassen C, et al. Identification of genes differentially regulated by the P210 BCR/ABL1 fusion oncogene using cDNA microarrays. Exp Hematol 2004; 32: 476-82.
57. Chen JL, Limnander A, Rothman PB. Pim-1 and Pim-2 kinases are required for efficient pre-B-cell transformation by v-Abl oncogene. Blood 2008; 111: 1677-85.
58. Schenone S, Brullo C, Botta M. Small molecules ATP-competitive inhibitors of FLT3: a chemical overview. Curr Med Chem 2008; 15: 3113-32.
59. Kim KT, Baird K, Ahn JY, et al. Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival. Blood 2005; 105: 1759-67.
60. Kim KT, Baird K, Davis S, et al. Constitutive Fms-like tyrosine kinase 3 activation results in specific changes in gene expression in myeloid leukaemic cells. Br J Haematol 2007; 138: 603-15.
61. Wang Z, Bhattacharya N, Meyer MK, et al. Pim-1 negatively regulates the activity of PTP-U2S phosphatase and influences terminal differentiation and apoptosis of monoblastoid leukemia cells. Arch Biochem Biophys 2001; 390: 9-18.
62. Hu YL, Passegué E, Fong S, Largman C, Lawrence HJ. Evidence that the Pim1 kinase gene is a direct target of HOXA9. Blood 2007; 109: 4732-8.
63. Dhanasekaran SM, Barrette TR, Ghosh D, et al. Delineation of prognostic biomarkers in prostate cancer. Nature 2001; 412: 822-6.
64. Cibull TL, Jones TD, Li L, et al. Overexpression of Pim-1 during progression of prostatic adenocarcinoma. J Clin Pathol 2006; 59: 285-8.
65. Xu Y, Zhang T, Tang H, et al. Overexpression of PIM-1 is a potential biomarker in prostate carcinoma. J Surg Oncol 2005; 92: 326-30.
66. Kim O, Jiang T, Xie Y, Guo Z, Chen H, Qiu Y. Synergism of cytoplasmic kinases in IL6-induced ligand-independent activation of androgen receptor in prostate cancer cells. Oncogene 2004; 23: 1838-44.
67. Chen WW, Chan DC, Donald C, Lilly MB, Kraft AS. Pim family kinases enhance tumor growth of prostate cancer cells. Mol Cancer Res 2005; 3: 443-51.
68. Xie Y, Xu K, Dai B, et al. The 44 kDa Pim-1 kinase directly interacts with tyrosine kinase Etk/BMX and protects human prostate cancer cells from apoptosis induced by chemotherapeutic drugs. Oncogene 2006; 25: 70-8.
69. Xie Y, Xu K, Linn DE, et al. The 44-kDa Pim-1 kinase phosphorylates BCRP/ABCG2 and thereby promotes its multimerization and drug-resistant activity in human prostate cancer cells. J Biol Chem 2008; 283: 3349-56.
70. Zemskova M, Sahakian E, Bashkirova S, Lilly M. The PIM1 kinase is a critical component of a survival pathway activated by docetaxel and promotes survival of docetaxel-treated prostate cancer cells. J Biol Chem 2008; 283: 20635-44.
71. Roh M, Gary B, Song C, et al. Overexpression of the oncogenic kinase Pim-1 leads to genomic instability. Cancer Res 2003; 63: 8079-84.
72. Roh M, Franco OE, Hayward SW, van der Meer R, Abdulkadir SA. A role for polyploidy in the tumorigenicity of Pim-1-expressing human prostate and mammary epithelial cells. PLoS One 2008; 3: e2572.
73. Chiang WF, Yen CY, Lin CN, et al. Up-regulation of a serinethreonine kinase proto-oncogene Pim-1 in oral squamous cell carcinoma. Int J Oral Maxillofac Surg 2006; 35: 740-5.
74. Reiser-Erkan C, Erkan M, Pan Z, et al. Hypoxia-inducible protooncogene Pim1 is a prognostic marker in pancreatic ductal adenocarcinoma. Cancer Biol Ther 2008; 7: 1352-9.
75. Qian J, Niu J, Li M, Chiao PJ, Tsao MS. In vitro modeling of human pancreatic duct epithelial cell transformation defines gene expression changes induced by K-ras oncogenic activation in pancreatic carcinogenesis. Cancer Res 2005; 65: 5045-53.
76. Cheng F, Weidner-Glunde M, Varjosalo M, et al. KSHV reactivation from latency requires Pim-1 and Pim-3 kinases to inactivate the latency-associated nuclear antigen LANA. PLoS Pathog 2009; 5: e1000324.
77. Qian KC, Wang L, Hickey ER, et al. Structural basis of constitutive activity and a unique nucleotide binding mode of human Pim-1 kinase. J Biol Chem 2004; 280: 6130-7.
78. Jacobs MD, Black J, Futer O, et al. Pim-1 ligand-bound structures reveal the mechanism of serine/threonine kinase inhibition by LY294002. J Biol Chem 2005; 280: 13728-34.
79. Cheney IW, Yan S, Appleby T, et al. Identification and structureactivity relationships of substituted pyridones as inhibitors of Pim-1 kinase. Bioorg Med Chem Lett 2007; 27: 1679-83.
80. Holder S, Zemskova M, Zhang C, et al. Characterization of a potent and selective small-molecule inhibitor of the PIM1 kinase. Mol Cancer Ther 2007; 6: 163-72.
81. Pogacic V, Bullock AN, Fedorov O, et al. Structural analysis identifies imidazo[1,2-b]pyridazines as PIM kinase inhibitors with in vitro antileukemic activity. Cancer Res 2007; 67: 6916-24.
82. Fedorov O, Marsden B, Pogacic V, et al. A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci USA 2007; 104: 20523-20528.
83. Grey R, Pierce AC, Bemis GW, et al. Structure-based design of 3- aryl-6-amino-triazolo[4,3-b]pyridazine inhibitors of Pim-1 kinase. Bioorg Med Chem Lett 2009; 19: 3019-22.
84. Shafer CM, Lindvall M, Bellamacina C, et al. 4-(1H-Indazol-5-yl)- 6-phenylpyrimidin-2(1H)-one analogs as potent CDC7 inhibitors. Bioorg Med Chem Lett 2008: 18: 4482-85.
85. Maksimoska J, Williams DS, Atilla-Gokcumen GE, et al. Similar biological activities of two isostructural rythenium and osmium complexes. Chem Eur J 2008; 14: 4816-22.
86. Qian K, Wang L, Cywin CL, et al. Hit to lead account of the discovery of a new class of inhibitors of Pim kinases and crystallographic studies revealing an unusual kinase binding mode. J Med Chem 2009; 52: 1814-27.
87. Gédu-Akué R, Rossignol E, Azzaro S, et al. Synthesis, kinase inhibitory potencies, and in vitro antiproliferative evaluation of new Pim kinase inhibitors. J Med Chem 2009; 52: 6369-81.
88. Tao ZF, Hasvold LA, Leverson JD, et al. Discovery of 3Hbenzo[ 4,5]thieno[3,2-d]pyrimidin-4-ones as potent, highly selective, and orally bioavailable inhibitors of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM) Kinases. J Med Chem 2009; 52: 6621-36.
89. Debreczeni JE, Bullock AN, Atilla GE, et al. Ruthenium halfsandwich complexes bound to protein kinase Pim-1. Angew Chem Int Ed 2006; 45: 1580-85.
90. Meggers E, Bregman H. Ruthenium half-sandwich complexes as protein kinase inhibitors: an N-succinimidyl ester for rapid derivatizations of the cyclopentadienyl moiety. Org Lett 2006; 8: 5465-68.
91. Bullock AN, Debreczeni JÉ, Fedorov OY, Nelson A, Marsden BD, Knapp S. Structural basis of inhibitor specificity of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM-1) kinase. J Med Chem 2005; 48: 7604-14.
92. Kirchmair J, Distinto S, Schuster D, Spitzer G, Langer T, Wolber G. Enhancing drug discovery through in silico screening: strategies to increase true positives retrieval rates. Curr Med Chem 2008; 15: 2040-53.
93. Pierce AC, Jacobs M, Stuver-Moody C. Docking study yields four novel inhibitors of the protooncogene Pim-1 kinase. J Med Chem 2008; 51: 1972-75.
94. Olla S, Manetti F, Crespan E, et al. Indolyl-pyrrolone as a new scaffold for Pim1 inhibitors. Bioorg Med Chem Lett 2009; 29: 1512-16.
95. Tong Y, Stewart KD, Thomas S, et al. Isoxazolo[3,4-b]quinoline- 3,4(1H,9H)-diones as unique, potent and selective inhibitors for Pim-1 and Pim-2 kinases: Chemistry, biological activities, and molecular modeling. Bioorg Med Chem Lett 2008; 18: 5206-08.
96. Xia Z, Knaak C, Ma J, et al. Synthesis and Evaluation of Novel Inhibitors of Pim-1 and Pim-2 Protein Kinases. J Med Chem 2009; 52: 74-86.
97. Sliman F, Blairvacq M, Durieu E, et al. Identification and structure- activity relationship of 8-hydroxy-quinoline-7-carboxylic acid derivatives as inhibitors of Pim-1 kinase. Bioorg Med Chem Lett 2010; 20: 2801-05.
98. Doudou S, Sharma R, Henchman RH, Sheppard DW, Burton NA. Inhibitors of PIM-1 kinase: a computational analysis of the binding free energies of a range of imidazo [1,2-b] pyridazines. J Chem Inf Model 2010; 50: 368-79.
99. Holder S, Lilly M, Brown ML. Comparative molecular field analysis of flavonoid inhibitors of the PIM-1 kinase. Bioorg Med Chem 2007; 15: 6463-73.